蛋白琥珀酸铁治疗重度贫血的效果观察

Observation on the effect of iron protein succinylate in treating severe anemia

目的分析蛋白琥珀酸铁治疗重度贫血患者的临床疗效。方法选择700例重度贫血患者作为本次观察对象,依据治疗药物的不同分为对照组和观察组,每组350例。对照组接受多糖铁复合物治疗,观察组采用蛋白琥珀酸铁治疗。比较两组患者治疗前后的血液学指标[红细胞计数(RBC)、血红蛋白(Hb)、平均红细胞体积(MCV)、平均红细胞血红蛋白含量(MCH)]、铁代谢指标[血清铁(SI)、铁蛋白(SF)和总铁结合力(TIBC)]水平及临床疗效、不良反应发生情况。结果对照组治疗前RBC、Hb、MCV、MCH、SI、SF、TIBC分别为(2.18±0.25)×10^(12)/L、(82.65±7.82)g/L、(67.45±4.47)fl、(21.23±2.35)pg、(6.35±1.12)μmol/L、(5.68±1.29)μg/L、(80.45±8.72)μmol/L,治疗后分别为(3.69±0.32)×10^(12)/L、(123.45±8.91)g/L、(73.61±4.82)fl、(24.57±2.80)pg、(16.37±1.72)μmol/L、(62.08±6.52)μg/L、(68.54±7.25)μmol/L;观察组治疗前RBC、Hb、MCV、MCH、SI、SF、TIBC分别为(2.15±0.31)×10^(12)/L、(82.57±7.93)g/L、(67.38±4.52)fl、(21.20±2.37)pg、(6.30±1.15)μmol/L、(5.62±1.34)μg/L、(80.56±8.81)μmol/L,治疗后分别为(5.34±0.48)×10^(12)/L、(129.58±9.74)g/L、(84.92±5.13)fl、(27.62±3.01)pg、(22.04±2.25)μmol/L、(80.76±7.98)μg/L、(61.89±6.43)μmol/L;治疗前,两组RBC、Hb、MCV、MCH、SI、SF、TIBC水平比较差异无统计学意义(P>0.05)。治疗后,两组患者的RBC、Hb、MCV、MCH、SI和SF均较治疗前升高,且观察组高于对照组;TIBC较治疗前降低,且观察组低于对照组,差异有统计学意义(P<0.05)。观察组患者治疗总有效率98.57%与对照组的98.86%比较,差异无统计学意义(P>0.05)。对照组患者的不良反应发生率1.71%与观察组的2.00%比较,差异无统计学意义(P>0.05)。结论针对重度贫血患者的治疗,采用蛋白琥珀酸铁治疗具有确切的临床疗效,可有效改善患者的铁代谢功能以及血液学指标浓度,同时具有较高的用药安全性。

Objective To analyze the clinical efficacy of iron protein succinylate in treating patienst with severe anemia.Methods 700 patients with severe anemia were selected as the observation subjects and divided into a control group and an observation group according to the different drugs used in treatment,with 350 cases in each group.The control group was treated with polysaccharide iron complex,and the observation group was treated with iron protein succinylate.Comparison was made on haematological indexes[red blood cell count(RBC),hemoglobin(Hb),mean corpuscular volume(MCV),mean corpuscular hemoglobin(MCH)]and iron metabolism indexes[serum iron(SI),serum ferritin(SF)and total iron binding capacity(TIBC)]before and after treatment,clinical efficacy,and occurrence of adverse reactions after treatment between the two groups.Results In the control group,RBC,Hb,MCV,MCH,SI,SF and TIBC before treatment were(2.18±0.25)×10^(12)/L,(82.65±7.82)g/L,(67.45±4.47)fl,(21.23±2.35)pg,(6.35±1.12)μmol/L,(5.68±1.29)μg/L and(80.45±8.72)μmol/L;after treatment,they were(3.69±0.32)×10^(12)/L,(123.45±8.91)g/L,(73.61±4.82)fl,(24.57±2.80)pg,(16.37±1.72)μmol/L,(62.08±6.52)μg/L and(68.54±7.25)μmol/L.In the observation group,RBC,Hb,MCV,MCH,SI,SF and TIBC before treatment were(2.15±0.31)×10^(12)/L,(82.57±7.93)g/L,(67.38±4.52)fl,(21.20±2.37)pg,(6.30±1.15)μmol/L,(5.62±1.34)μg/L and(80.56±8.81)μmol/L;after treatment,they were(5.34±0.48)×10^(12)/L,(129.58±9.74)g/L,(84.92±5.13)fl,(27.62±3.01)pg,(22.04±2.25)μmol/L,(80.76±7.98)μg/L and(61.89±6.43)μmol/L.Before treatment,there was no significant difference in RBC,Hb,MCV,MCH,SI,SF and TIBC levels between the two groups(P>0.05).After treatment,RBC,Hb,MCV,MCH,SI and SF in both groups were higher than those before treatment,and the observation group was higher than the control group;TIBC in both groups was lower than that before treatment,and the observation group was lower than the control group;the difference was statistically significant(P<0.05).The total effective rate of treatment in the observation group was 98.57%,and there was no statistically significant difference compared to the control group's 98.86%(P>0.05).The incidence of adverse reactions in the control group was 1.71%,and there was no statistically significant difference compared to the observation group's 2.00%(P>0.05).Conclusion For patients with severe anemia,iron protein succinylate has a definite clinical effect,and can effectively improve the iron metabolism function and hematological index concentration of patients,and has a high drug safety.